THE FEATURES OF PSYCHOSOCIAL FACTORS IN MENOPAUSAL DISORDERS

DOI: https://doi.org/10.29296/25877305-2022-12-09
Issue: 
12
Year: 
2022

Professor A. Sulima, MD; Associate Professor Z. Rumyantseva, Candidate
of Medical Sciences; N. Efremova
Institute «Medical Academy named after S.I. Georgievsky» V.I. Vernadsky Crimean Federal University, Simferopol, Russia

The features of the course and correction of menopausal syndrome (MS) are largely determined by concomitant psychosocial factors (PSRFs), as well as the presence of extragenital pathology. In this regard, the issues of studying PSRFs in women with MS and concomitant somatic morbidity are quite relevant. The aim is to study the main PSRFs in women with MS and concomitant extragenital pathology. Subjects and methods. A prospective comprehensive clinical, laboratory and psychosocial examination of 100 women with MS was conducted, which were divided into two groups: the main group – 50 patients with MS on the background of extragenital pathology; the control group – 50 patients with MS without extragenital pathology. Results. The study revealed a significantly higher level of depression and reactive anxiety in women who complain of MS and suffer from extragenital pathology. These psychological disorders can be explained by a violation of stress coping mechanisms, as well as the predominance of immature styles of defense (passive aggression, detachment from the situation, somatization). Conclusions. A complex of psychological problems leads to a deterioration in the quality of life with an average level of psychosocial stress. The obtained results should be used in the development of a complex of prognostic and therapeutic and preventive measures.
Keywords: 
menopause
psychological and social factors
anxiety
depression
treatment.

References: 
  1. World health statistics 2019: monitoring health for the SDGs, sustainable development goals. World Health Organization, 2019. URL: https://apps.who.int/ iris/handle/10665/324835
  2. Federal’naya sluzhba gosudarstvennoi statistiki, 2019. Zdravookhranenie v Rossii. 2019: Statisticheskii sbornik. M.: Rosstat, 2019; 170 s. (in Russ.).
  3. Dreval A.V. Menopause (lecture). RMJ. 2018; 1 (I): 3–7 (in Russ.).
  4. Dvoryanskiy S.A., Emelyanova D.I., Yagovkina N.V. Climacteric syndrome: current status of the issue (literature review). Vyatskii meditsinskii vestnik. 2017; 1 (53): 7–15 (in Russ.).
  5. Gavisova A.A., Tverdikova M.A., Balushkina A.A. Klimaktericheskii sindrom: osobennosti terapii psikhoemotsional’nykh narushenii. RMJ. 2009; 17 (20): 1408–11 (in Russ.).
  6. Low D.A., Hubing K.A., Del Coso J. et al. Mechanisms of cutaneous vasodilation during the postmenopausal hot flash. Menopause. 2011; 18 (4): 359–65. DOI: 10.1097/gme.0b013e3181f7a17a
  7. Lucas R.A., Ganio M.S., Pearson J. et al. Brain blood flow and cardiovascular responses to hot flashes in postmenopausal women. Menopause. 2013; 20 (3): 299–304. DOI: 10.1097/gme.0b013e31826e45f0
  8. Kostroma Ya.V., Belyaeva E.N., Khazova E.L. et al. Assessment of the severity of menopausal syndrome and psychosomatic peculiarities. Journal of Obstetrics and Women’s Diseases. 2019; 68 (1): 13–20 (in Russ.). DOI: 10.17816/JOWD68113-20
  9. Ilyina I.Yu., Dobrokhotova Yu.E., Ibragimova D.M. Alternative methods of treatment of menopausal syndrome. RMJ. 2018; 26 (2–1): 8–12 (in Russ.).
  10. Zaydieva Y.Z. Alternative therapy of menopausal disorders in women of climacterical age (literature review). RMJ. 2017; 12: 873–8 (in Russ.).
  11. Unanyan A.L., Kuzenkova N.N., Sidorova I.S. et al. Menopausal therapy: benefits and risks. RMJ. 2017; 15: 1128–34 (in Russ.).
  12. Soules M.R., Sherman S., Parrott E. et al. Stages of Reproductive Aging Workshop (STRAW). J Womens Health Gend Based Med. 2001; 10: 843–8. DOI: 10.1089/152460901753285732
  13. Klinicheskie rekomendacii [Tekst]: Menopauza i klimaktericheskoe sostoyanie u zhenshchiny. Russian Society of Obstetricians and Gynaecologists. M., 2021 (in Russ.).
  14. Skrebitsky V.G., Kasyan A.P., Povarov I.S. Biological Activity and Basic Mechanisms of Action of Selang – a Neuropeptide Product. Nervnye bolezni. 2016; 4: 52–7 (in Russ.).
  15. Verbenko V.A., Fedorov V.N. The using a new anxiolytic peptide "Selank" in the therapy of psychogenic binge eating disorder. Tavricheskii zhurnal psikhiatrii. 2016; 20 (3): 5–13 (in Russ.).
  16. Verbenko V.A., Shakina T.A. Effectiveness of new synthesized analogue of endogenous peptide taftcin – Selank in therapy of adjustment and posttraumatic stress disorders. Medical alphabet. 2017; 3 (32): 21–6 (in Russ.).
  17. Tereshchenko O.N., Kost N.V., Medvedev V.E. et al. Therapy of anxiety disorders in general practice by peptide preparation Selank. Arkhiv vnutrennei meditsiny. 2016; 6 (S1): 115–6 (in Russ.).
  18. Lapochkina N.P., Matasheva A.V., Krupenina E.A. Selective inhibitors of serotonin reverse capture in the correction of psycho-vegetative disorders in women with climacteric syndrome. Vestnik Ivanovskoi meditsinskoi akademii. 2015; 20 (4): 34–8 (in Russ.).
  19. Starikov P., Fedorov V. The use of Selank in the treatment of autonomic and psychoemotional disorders in women with climacteric syndrome. Vrach. 2019; 30 (12): 48–53 (in Russ.). DOI: 10.29296/25877305-2019-12-13